There have been numerous instances where dinner table conversations have sparked transformative ideas.
The framework for AIDDISON, Merck KGaA’s AI-powered drug discovery platform too was set out amid the clinking of cutlery when...
Merck KGaA’s AI Platform Architect On Redefining The Drug Discovery Process
The head of AI and automation in drug discovery at Merck KGaA’s life science business talked to Scrip about the company’s AI-powered platform that leverages a “gold mine” of proprietary R&D data, better in silico predictions and the next frontier of AI.
More from Business
• By
Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.
• By
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.
• By
Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.
• By
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
More from Digital Technologies
• By
Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.
• By
A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges
• By
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.